{"id":"hpp2101","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HPP2101 activates the glucagon-like peptide-1 (GLP-1) receptor, which enhances insulin secretion in response to glucose, slows gastric emptying, and promotes satiety. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient compliance while maintaining sustained metabolic benefits.","oneSentence":"HPP2101 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:24.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05024721","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-08-09","conditions":"Gastritis","enrollment":326}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HPP2101","genericName":"HPP2101","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HPP2101 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}